Next |
home / stock / vstm / vstm message board
Subject | By | Source | When |
---|---|---|---|
Happy I hit and run. I would consider | Harbor6460 | investorshub | 06/09/2023 4:06:50 PM |
$VSTM The gaining | Tartiaboy | investorshub | 06/08/2023 9:42:19 PM |
$VSTM news all the way baby | Tartiaboy | investorshub | 06/04/2023 12:16:39 PM |
They definite are diluting. They need money. | Harbor6460 | investorshub | 05/29/2023 2:44:48 PM |
highest volume in history -insert dd- | The Night Stalker | investorshub | 05/29/2023 5:53:28 AM |
$VSTM Time for this to show some returns | Harbor6460 | investorshub | 05/28/2023 5:08:47 PM |
Yep | Harbor6460 | investorshub | 05/26/2023 8:32:36 PM |
nice | knrorrel | investorshub | 05/26/2023 7:49:51 PM |
oh my | The Night Stalker | investorshub | 05/26/2023 7:37:35 PM |
Looks like dilution | Triple nickle | investorshub | 05/26/2023 7:28:31 PM |
Looks like real support at a dollar. Could | KeepOn | investorshub | 05/26/2023 6:37:35 PM |
Added the dip | Triple nickle | investorshub | 05/26/2023 6:10:34 PM |
I post so others can ride with me | Triple nickle | investorshub | 05/26/2023 5:26:57 PM |
$VSTM: Well, Capt. T-N, you certainly scored MONSTER | Invest-in-America | investorshub | 05/26/2023 5:23:00 PM |
Halted? | Harbor6460 | investorshub | 05/26/2023 5:15:06 PM |
Nice call | jchords | investorshub | 05/26/2023 4:57:04 PM |
Okay nice run folks | Triple nickle | investorshub | 05/26/2023 4:26:49 PM |
.75 comin up 1.00 soon | Triple nickle | investorshub | 05/26/2023 4:21:41 PM |
LV2 still looks real thin .75 ? | Triple nickle | investorshub | 05/26/2023 3:46:10 PM |
Really Good Friday here | Triple nickle | investorshub | 05/26/2023 3:44:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...